Singapore, April 7 -- South Korea-based startup ABL Bio Inc. has announced a worldwide licensing agreement enablingGlaxoSmithKline Pharmaceuticals (GSK) to develop novel medicines for neurodegenerative diseases by utilising ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B.

The agreement aims to develop multiple programmes for novel targetsacross therapeutic modalities including antibody, polynucleotide or oligonucleotides, such as siRNA and ASOs,to address significant unmet medical needs of patients suffering from neurodegenerative conditions.

The blood-brain barrier (BBB) serves as a protective barrier that restricts the entry of harmful substances and agents into the brain and is considered a significant obstacle in the...